학술논문
Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal Disease Worldwide: Systematic Review.
Document Type
Article
Author
Le Doare, Kirsty; O'Driscoll, Megan; Turner, Kim; Seedat, Farah; Russell, Neal J.; Seale, Anna C.; Heath, Paul T.; Lawn, Joy E.; Baker, Carol J.; Bartlett, Linda; Cutland, Clare; Gravett, Michael G.; Ip, Margaret; Madhi, Shabir A.; Rubens, Craig E.; Saha, Samir K.; Schrag, Stephanie; Meulen, Ajoke Sobanjo-ter; Vekemans, Johan; Kampmann, Beate
Source
Subject
*STREPTOCOCCAL disease prevention
*ANTIBIOTICS
*DECISION making
*CLINICAL pathology
*HEALTH
*MEDICAL information storage & retrieval systems
*MANAGEMENT
*MEDICAL societies
*MEDLINE
*META-analysis
*MICROBIAL sensitivity tests
*ONLINE information services
*PERINATAL death
*PROFESSIONAL associations
*RESEARCH funding
*STREPTOCOCCAL diseases
*STREPTOCOCCUS
*SURVEYS
*SYSTEMATIC reviews
*BIBLIOGRAPHIC databases
*HUMAN services programs
*DISEASE incidence
*ANTIBIOTIC prophylaxis
*INTRAPARTUM care
*PREGNANCY
*DISEASE risk factors
DEVELOPING countries
DEVELOPED countries
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1058-4838
Abstract
Background. Intrapartum antibiotic chemoprophylaxis (IAP) prevents most early-onset group B streptococcal (GBS) disease. However, there is no description of how IAP is used around the world. This article is the sixth in a series estimating the burden of GBS disease. Here we aimed to review GBS screening policies and IAP implementation worldwide. Methods. We identified data through (1) systematic literature reviews (PubMed/Medline, Embase, Literature in the Health Sciences in Latin America and the Caribbean [LILACS], World Health Organization library database [WHOLIS], and Scopus) and unpublished data from professional societies and (2) an online survey and searches of policies from medical societies and professionals. We included data on whether an IAP policy was in use, and if so whether it was based on microbiological or clinical risk factors and how these were applied, as well as the estimated coverage (percentage of women receiving IAP where indicated). Results. We received policy information from 95 of 195 (49%) countries. Of these, 60 of 95 (63%) had an IAP policy; 35 of 60 (58%) used microbiological screening, 25 of 60 (42%) used clinical risk factors. Two of 15 (13%) low-income, 4 of 16 (25%) lower-middle--income, 14 of 20 (70%) upper-middle--income, and 40 of 44 (91%) high-income countries had any IAP policy. The remaining 35 of 95 (37%) had no national policy (25/33 from low-income and lower-middle--income countries). Coverage varied considerably; for microbiological screening, median coverage was 80% (range, 20%--95%); for clinical risk factor--based screening, coverage was 29% (range, 10%--50%). Although there were differences in the microbiological screening methods employed, the individual clinical risk factors used were similar. Conclusions. There is considerable heterogeneity in IAP screening policies and coverage worldwide. Alternative global strategies, such as maternal vaccination, are needed to enhance the scope of global prevention of GBS disease. [ABSTRACT FROM AUTHOR]